COGT stock icon

Cogent Biosciences
COGT

$8.36
1.65%
 

About: Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Employees: 164

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 12 analysts
0
News positive %
of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 4 (+2) [Q1 2024]

93% more call options, than puts

Call options by funds: $1.3M | Put options by funds: $677K

63% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 38

37% more capital invested

Capital invested by funds: $538M [Q4 2023] → $734M (+$197M) [Q1 2024]

2% more funds holding

Funds holding: 144 [Q4 2023] → 147 (+3) [Q1 2024]

10% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 31

1.06% less ownership

Funds ownership: 106.2% [Q4 2023] → 105.14% (-1.06%) [Q1 2024]

Research analyst outlook

12 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$8
4%
downside
Avg. target
$14.92
78%
upside
High target
$20
139%
upside

12 analyst ratings

positive
75%
neutral
25%
negative
0%
HC Wainwright & Co.
Robert Burns
127%upside
$19
Buy
Reiterated
17 Jun 2024
Needham
Ami Fadia
115%upside
$18
Buy
Reiterated
17 Jun 2024
Wedbush
David Nierengarten
20%upside
$10
Neutral
Reiterated
24 May 2024
HC Wainwright & Co.
Robert Burns
127%upside
$19
Buy
Reiterated
13 May 2024
Needham
Ami Fadia
115%upside
$18
Buy
Reiterated
8 May 2024

Financial journalist opinion

Based on 3 articles about COGT published over the past 30 days